The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people with Parkinson’s disease, according to a new study. Researchers ...

Treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide had no disease-modifying effects on movement, symptom severity or brain imaging in patients with Parkinson’s disease ...

(HealthDay News) — The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson’s disease severity, according to a study published online Feb. 4 in The ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's disease, finds a new study led by UCL researchers. The world's largest and ...

Two-year data from a phase 3 trial of exenatide in Parkinson’s is due later this year and could help answer that question, said Prof Foltynie. Bain Capital has agreed to buy Mitsubishi Tanabe ...

Prayagraj authorities will enforce a No Vehicle Zone in the Mela area and the city from 11 February 2025 for the Maghi Purnima snan at the Mahakumbh. Only essential and emergency vehicles are ...

Elastogenesis is the term that collectively describes the hierarchical process of elastic fiber formation, and is comprised of distinct phases: tropoelastin synthesis, coacervation, cross-linking, and ...

US President Donald Trump suggested that Ukraine might eventually become part of Russia, ahead of Vice President JD Vance's meeting with Ukrainian President Zelenskyy. Trump emphasized that future ...